The recently established the Institute of Molecular and Translational Medicine (IMTM), Faculty of Medicine and Dentistry, Palacký University in Olomouc is one of the most influential research projects carried out in the Czech Republic. The IMTM‘s mission is basic and translational biomedical research with the goal to understand the underlying causes of cancer and infectious diseases and to develop future human medicines and diagnostics. The initiator of the formation was The Palacký University in Olomouc in close partnership with the University Hospital in Olomouc, the Institute of Chemical Technology in Prague and the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic.
Unique capabilities • The flexibility of our drug and biomarker discovery engine components to dynamically accommodate the project needs and create an optimal configuration is one of the greatest assets of the Institute. Strategically, it allows us as well as our academic and industrial partners to maximize drug and biomarker discovery resources for both exploratory and developmental projects. Industrial partners, especially large pharma can capitalize on such a flexible and adaptive research model that may be more difficult to practice in a large organization. • Cancer research expertise with cutting-edge technology platforms complemented with clinical oncology programs at the University Hospital in Olomouc and other collaborating hospitals. • Unique tissue/fluid biobanking complemented with clinical data. • IMTM is the national node for EATRIS (European Advance Translational Medicine Infrastructure).
Formation of the IMTM is funded via project Biomedicine for Regional Development and Human Resources (BIOMEDREG) financed by the European Regional Development Fund and the national budget of the Czech Republic through the Operational Program Research and Development for Innovation.